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Lipid toxicityPhospholipid aldehydes represent a particular subclass of lipid oxidation products. They are chemically reac-
tive and can form Schiff bases with proteins and aminophospholipids. As chemically bound molecular entities
they modulate the functional properties of biomolecules in solution and the surface of supramolecular sys-
tems including plasma lipoproteins and cell membranes. The lipid–protein and lipid–lipid conjugates may
be considered the active primary platforms that are responsible for the biological effects of aldehydopho-
spholipids, e.g. receptor binding, cell signaling, and recognition by the immune system. Despite the fact
that aldehydophospholipids are covalently associated, they are subject to exchange between nucleophiles
since their imine conjugates are not stable. As a consequence, aldehydophospholipids exist in a dynamic
equilibrium between different “states” depending on the lipid and protein environment. Aldehydophospho-
lipids may also contribute to the systemic administration and activity of oxidized phospholipids by inducing
release of microparticles by cells. These effects are lipid-speciﬁc. Future studies should help clarify the mech-
anisms and consequences of these membrane-associated effects of “phospholipid stress”. This article is part
of a Special Issue entitled: Oxidized phospholipids—their properties and interactions with proteins.
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The major fraction of diacyl glycerophospholipids in the phospho-
lipid bilayers of cell membranes and the phospholipid monolayers of
plasma lipoproteins and intracellular lipid droplets shows a common
fatty acid pattern. In position sn-1, they contain a saturated fatty acid
whereas the sn-2 hydroxy group of glycerol is esteriﬁed to a mono- or
polyunsaturated fatty acid. The most abundant phospholipid classes
contain ethanolamine and choline head groups. Serine and inositol
phospholipids, although functionally very important and speciﬁc,
are less abundant. Except for the liver, animal and human cell mem-
branes contain large amounts of ether phospholipids [1], namely
plasmalogens (1-O-alkenyl-2-acyl-sn-glycero-3-phospholipids) and
lower amounts of their saturated 1-O-alkyl analogs. Only smallFig. 1. Chemical structures of lipid oxidation products and labeled lipid analogs. Chemical sconcentrations of ether choline and ethanolamine phospholipids are
found in plasma lipoproteins [1].
Under the conditions of oxidative stress, the polyunsaturated acyl
chains are preferred targets of free radical attack of the bisallylic hy-
drogen atoms. Hydrogen abstraction is the ﬁrst step in this process
which is eventually followed by a series of modiﬁcations and frag-
mentations of the sn-2 acyl chain. As a consequence, a great variety
of oxidized phospholipids is formed. Almost all of them are character-
ized by a saturated fatty acyl chain in position sn-1 and oxidized fatty
acid residue in the sn-2 position. An exception is 1-formyl phospho-
lipids that can be formed upon oxidation of the 1-enolether bond of
plasmalogens [2].
Formation of phospholipid sn-2-aldehydes always requires frag-
mentation reactions. As a consequence, the respective acyl chainstructures of oxidized phospholipids (Panels A,C,D) and labeled lipid analogs (Panel B).
Fig. 2.Molecular dynamics of oxidized phospholipids in bilayer membranes. Shown are
snapshots of single PazePC and PoxnoPC molecules. The oxidized sn-2 chains are
shown in yellow, except for the terminal functional group. The rest of the molecules
are shown in blue. The horizontal black line represents the approximate average loca-
tion of the phosphate groups in one bilayer leaﬂet. This data provides evidence that the
polar sn-2 chain of oxPL pocks out to the aqueous phase (PazePC) or is located at the
hydrophobic/hydrophilic interface (PoxnoPC). Therefore, it may be available for inter-
actions with proteins from in- and outside the cells.
Figure taken from Khandelia and Mourtisen, 2009, Biophys.J.96 [14].
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ed counterparts. Most of the oxidized precursor phospholipids con-
taining chiral centers in the modiﬁed sn-2 acyl residue are racemic.
Therefore, it was concluded that they are predominantly generated
by chemical oxidation involving transition metal ions instead of ste-
reospeciﬁc enzymatic modiﬁcation [3,4].
Many aldehydophospholipids are accompanied by their higher ox-
idized carboxylate derivatives in their biological environment. Al-
though the structural difference between these compounds is small,
the mechanisms underlying their activities are different because the
phospholipid aldehydes are chemically reactive (Schiff base forma-
tion with proteins and aminophospholipids) whereas the carboxy-
phospholipids can only physically interact with other biomolecules
[4–6]. Both types of oxidized phospholipids have frequently been
compared in the literature. In this review we also make an attempt
to highlight the relationship between biological lipid activity and dif-
ferences in lipid structure.
The structural motifs of oxidized phospholipids have been de-
scribed in several reviews [4,7,8]. This article focuses on those
compounds that contain aldehyde functions. The majority of oxi-
dized phospholipids identiﬁed so far contain choline head groups.
Representative chemical structures of aldehydo choline phospho-
lipids and their carboxy analogs are shown in Fig. 1. The γ-
hydroxyalkenal-PCs HOOA-PC/HOdiA-PC and KOOA-PC/KOdiA-PC
are formed by reduction of PC hydroperoxides followed by fragmen-
tation of the resulting hydrodienes [4]. The aldehydes HOOA-PC and
KOOA-PC share the highly reactive γ-hydroxy-α,β-alkenal element
with hydroxynonenal (HNE) which is released after oxidation from
the ω-end of the parent fatty acid [9]. As a consequence, these com-
pounds show a more complex reactivity towards nucleophiles such
as Schiff base formation and Michael addition [9,10].
Further fragmentation of phospholipid-associated hydroxyalke-
nals leads to the formation of the truncated phospholipids POVPC/
PGPC and PoxnoPC/PazePC. The respective compounds are oxidation
products of 1-palmitoyl-2-arachidonoyl- and 1-palmitoyl-2-lino-
leoyl-sn-glycero-3-phosphocholine, respectively. POVPC/PGPC con-
tain shorter oxidized acyl chains and, as a consequence, are more
polar than PoxnoPC/PazePC. The structures of the former compounds
are more closely related to platelet activating factor which only con-
tains a very short acetyl residue in position sn-2 and a long 1-O-alkyl
chain in position sn-1 of glycerol.
Isolevuglandins are formed via an entirely different pathway.
Nonenzymatic reaction of phospholipid-associated arachidonic acid
with two oxygen molecules generates endoperoxide intermediates
that are further modiﬁed by several consecutive reactions leading to
isoprostanes containing a ﬁve-membered ring or isolevuglandins
(no cyclisation). In contrast to the truncated phospholipids, both
lipid subclasses still contain a long-chain carboxylic acid residue in
position sn-2. However, these acyl chains are polar due to the pres-
ence of functional groups [4].
Biological activities of oxidized phospholipids have initially been
studied using lipid mixtures obtained after oxidation of polyunsatu-
rated phospholipids, e.g. PAPC, PLPC or biological lipid extracts. For
several years, the number of biochemical and biophysical studies
using chemically deﬁned oxidized phospholipids is increasing. Most
of these studies have been performed using the truncated phospho-
lipids POVPC/PGPC and PoxnoPC/PazePC, since simple procedures
are available for the preparation of these lipids. Chemical syntheses
of more complex oxidized phospholipids, e.g. isoprostanes, have
also been reported but are very time-consuming. Thus, the develop-
ment of facile procedures for the synthesis of chemically deﬁned
phospholipid oxidation products will be a continuous challenge for
the future. Chemically pure compounds will not only be needed as
substrates for biochemical and biophysical investigations, but also
as standards for the rapidly increasing ﬁeld of lipidomics based on
mass spectrometry of lipid analytes.2. Aldehydophospholipids talk biophysics and biochemistry
The chemical reactivity of aldehydophospholipids towards nucleo-
philes is intimately associatedwith their amphipathic nature and their
associationwith lipid–water interfaces.Whereas the reactivity of such
compounds in organic solution is largely diffusion-controlled, chemi-
cal reactions with amino (or thiol) groups of proteins and aminopho-
spholipids in membranes and lipoproteins depend on the localization
of the functional aldehyde group, the molecular lipid mobility and the
steric constraints due to lateral lipid and protein packing. POVPC and
Poxno-PC on the one hand and PGPC and Paze-PC on the other hand
are amphiphiles that are linked to the phospholipid phase only by
one long hydrophobic acyl chain. The fragmented sn-2 fatty acyl sub-
stituent in these molecules is polar and can be expected to fold back
to the membrane interface or surface [11,12]. This assumption is sup-
ported by in silico studies by Wong-ekkabut [13] and by Khandelia
and Mouritsen [14]. The latter authors simulated the molecular con-
formations of PGPC and POVPC in a phospholipid bilayer (Fig. 2). It
was found that PGPC adopts an extended conformation with the neg-
atively charged sn-2 carboxylate group stretching into the water
phase. In contrast, the electroneutral but polar sn-2 aldehyde group
of POVPC remains in the hydrophobic–hydrophilic membrane inter-
face which makes it available for chemical reactions with the amino
groups of membrane-associated proteins and phospholipids.
Several biophysical data have already been published that are in
line with the model of Khandelia and Mouritsen [14]. Probing mem-
brane properties with a set of ﬂuorophores provided evidence that
the microenvironment sensed in POVPC aggregates is less polar and
less hydrated than in artiﬁcial membranes containing PGPC [15]. The
dipolar surface potential of POVPC is also lower than the correspond-
ing value for PGPC [15]. Both phenomena are in agreement with the
supra-molecular properties of both oxidized phospholipids described
above. The same tendencies were found in comparative studies on
the longer-chain homologs Poxno-PC and Paze-PC. Fluorescencemea-
surements again revealed lower micropolarities in the aldehydopho-
spholipid (Poxno-PC) membranes. However, the differences in
polarity measured for the slightly more hydrophobic Poxno-PC and
Paze-PC are smaller than those between POVPC and PGPC. Beranova
et al. [16] showed that a carboxy residue on the truncated sn-2 chain
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membrane lipids. For the aldehydo-phospholipid POVPC the opposite
effect was observed.
In addition to high polarity, hydration and mobility, aldehydopho-
spholipids and other structurally related lipid oxidation products
show another distinct molecular feature, namely a conical molecular
shape. The polar sn-2 acyl chains become part of a huge polar head
group possessing a much larger cross sectional area than the long hy-
drophobic sn-1 acyl chain. As a consequence [17,18], such lipids can be
expected to induce the formation of positive membrane curvatures
leading to a series of structural and functional consequences. First of
all, the formation of membrane vesicles can be facilitated. Single mol-
ecule microscopy revealed that a ﬂuorescent PGPC analog was rapidly
enriched in lipid patches within milliseconds followed by release of
ﬂuorescent vesicles inside the cells [19]. Similar experiments using a
ﬂuorescent POVPC analog are currently under way in this laboratory.
The contribution of the oxidized phospholipids to the extracellular re-
lease of membrane vesicles (membrane blebbing, e.g. in apoptotic
cells) is not so clear. POVPC is less efﬁcient in this regard than PGPC
(Stemmer et al., unpublished), very likely because it does not move
freely in the membrane due to chemical reaction (imine formation)
with proteins and aminophospholipids. The “curvature effect” of oxi-
dized phospholipids may also lead to functional consequences for
the proteins preferring a particular membrane environment. The re-
sultant increase in membrane heterogeneity could lead to preferred
partitioning of proteins (and aminophospholipids) in particular sub-
phases and alter their activities and reactivities. According to data
obtained from a proteomic analysis, Schiff base formation of polypep-
tides with a ﬂuorescent POVPC analog in living cells is very selective
(see below). This effect can be due to differences in pK, transversal lo-
calization and steric accessibility of protein amino groups as well as
the lateral protein partitioning in lipid phases induced by the oxidized
phospholipids [20].
3. Schiff base formation by aldehydophospholipids
Oxidized phospholipids are electrophiles. Depending on their
chemical structures, they can interact with other biomolecules in an
entirely physicalmanner or chemically, leading to a variety of covalent
conjugates. Aldehydophospholipids represent a typical subclass of
chemically reactive lipid oxidation products. They show the capacity
of modifying free amino groups in small molecules (amino acids, ami-
nophospholipids) as well as polypeptides by Schiff base formation
[21]. As a consequence of chemical modiﬁcation, localization, associa-
tion and activity of enzymes and signaling proteins may be altered. If
lipid–lipid adducts are formed, membrane organization may change
profoundly thereby affecting lateral lipid organization, local mem-
brane curvatures, and lipid mobilities. In the end, these lipid-
associated effects may affect membrane protein function, membrane
stability and the tendency to release membrane vesicles (exo- and
endosomes).
A great deal of information is available about adduct formation be-
tween biological nucleophiles and hydroxynonenal (HNE) [22] which
is a fragment released from theω-end of a (phospholipid-bound) fatty
acyl chain under oxidative stress. In contrast to HNE, information on
conjugation of phospholipid aldehydes to biomolecules and its physi-
ological consequences is still scarce. Inspection of the greatly different
chemical structures and polarities of both compound classes shows
that modiﬁcation of biomolecules by HNE or oxidized phospholipids
may elicit quite different effects. Modiﬁcation of proteins by water-
soluble HNE will change protein solubility and localization to a lesser
extent as compared to modiﬁcation by a phospholipid aldehyde [23].
Schiff base formation with the latter compounds leads to addition of
a hydrophobic fatty acyl chain to the nucleophilic target, which repre-
sents a potential membrane anchor. This assumption is in line with
data published by Kinnunen and collaborators. They found thatPoxno-PC improves membrane association of phospholipase A2 and
as a consequence the activity of this lipid degrading enzyme [24].
Most aldehydophospholipids contain only one long-chain fatty
acid. As a consequence, they efﬁciently partition between the mem-
brane lipid and the water phase. Their nucleophilic targets can be hy-
drophobic and water soluble proteins, membrane phospholipids as
well as small polar molecules (e.g. amino acids). The following chap-
ters describe Schiff base formation with the respective biomolecules
in solution, in plasma lipoproteins, in artiﬁcial and biological mem-
brane preparations, in live cells and in tissues. Finally, the role of
these phenomena in pathophysiology is discussed. Since lipoprotein
modiﬁcation and lipoprotein-cell interactions play a key role in ath-
erogenesis, this aspect of oxidized phospholipids has so far received
most attention. Implications of Schiff base formation by these com-
pounds in other diseases have also been recognized but are not so
well characterized [10,22,25–29].
3.1. Modiﬁcation of proteins in solution
Aldehydophospholipids react with α- and ε-amino groups of
amino acids and derivatives (e.g. lysine, valine, lysine methyl ester)
to form Schiff bases. Typical imines were identiﬁed after chemical re-
duction and analysis of the resulting amines using LC-ESI MS (see
below) [21]. The same functional groups are also modiﬁed by phos-
pholipid aldehydes in proteins (N-terminal and lysyl amino residues,
respectively). For this study, a mixture of 1-palmitoyl- (70%) and 1-
stearoyl-2-(9-oxo)nonanoyl-glycerophosphocholine (30%) was pre-
pared by ozonolysis of egg yolk phosphatidylcholine. The resulting
preparation containing various oxidized lipids was used to deter-
mine the modiﬁcation of free amino groups in horse skeletal muscle
apomyoglobin which contains one free N-terminal amino acid and
19 ε-lysyl amino group. Interestingly, only two to four phospholipid
aldehydes reacted with the protein depending on reaction condi-
tions. Obviously, there is a preference of lipid aldehydes for certain
amino groups in a protein depending on accessibility and proton-
ation of the nitrogen atom (for analysis of Hsp 90 modiﬁcation by
HNE, see [30]). In this context, it has to be emphasized that the Schiff
bases (imines) generated from phospholipid aldehydes and amines
have to be stabilized before analysis by chemical reduction with
NaCNBH3 giving the corresponding stable amines.
Kinnunen and colleagues reported that modiﬁcation of polypep-
tides by Poxno-PC improved protein binding to artiﬁcial membranes
[31]. The presence of the truncated phospholipid led to better inter-
calation of several antimicrobial peptides in phospholipid mono-
layers and bilayers (liposomes). Such an effect was not observed if
the lipid aldehyde was replaced by Paze-PC which contains an ω-
carboxy group in the oxidized sn-2 acyl chain. This data is in agree-
ment with the assumption that alkylation by the oxidized phospho-
lipids generates a hydrophobic tail which anchors the peptide in
the membrane [31]. Apart from possible effects of oxidized phospho-
lipids on protein structure, membrane anchoring might also contrib-
ute to the stimulation of phospholipase A2 activity on DPPC by
Poxno-PC [24]. In the absence of the lipid aldehyde, a lag phase was
observed before DPPC degradation could be detected. Addition of
Poxno-PC entirely abolished the initial delay and led to immediate
lipid degradation [22].
Formation of covalent protein conjugates with aldehydophospho-
lipids can be visualized if ﬂuorescent lipid analogs are used as electro-
philes. Stemmer et al.[20] prepared complexes of bovine serum
albumin with a ﬂuorescent POVPC derivative carrying BY as ﬂuoro-
phore at the head group (BY-POVPC). After reductive stabilization
(see above), a ﬂuorescent band was detected after SDS electrophore-
sis, showing the same electrophoretic mobility as the unlabeled pro-
tein. BSA can noncovalently bind one molecule of lyso-PC [32]. The
complex of this protein with BY-POVPC is in addition stabilized by a
covalent imine bond. Whereas amines are stable, imines are not.
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philes, e.g. proteins leads to lipid exchange between the protein com-
petitors. This phenomenon shows that phospholipid aldehydes are
exchangeable in the biological milieu despite the fact that they are co-
valently bound to their protein (or aminophospholipid) targets (see
also lipoprotein and cell binding).
3.2. Modiﬁcation of protein components in lipoproteins
The plasma lipoproteins LDL and HDL play a key role in the devel-
opment and progress of atherosclerosis. Whereas LDL is proathero-
genic, certain HDL subclasses exert a protective effect. Under the
conditions of oxidative stress, the protein and lipid components of
both particles are subject to modiﬁcation by free radical-mediated
and nonradical mechanisms turning the properties of both lipopro-
teins to the unfavorable side. From in vitro experiments with oxidized
lipoproteinmodels, much informationwas obtained as to the relation-
ship between the extent and the mode of oxidation on the one hand
and the biological activities of the modiﬁed lipoproteins on the other
hand. In minimally modiﬁed lipoproteins (e.g. obtained after oxida-
tion with Fe2+ ions), mostly the lipid components are modiﬁed [33].
Phospholipid aldehydes are already present at this stage but apoB
modiﬁcation by these and other (e.g. HNE, MDA) electrophiles is not
efﬁcient enough, since mmLDL is still recognized by the classical
apoB receptor [5]. Therefore, it is a good system to study the toxic ef-
fects of LDL lipids in vascular cells beyond receptor-mediated uptake
of the entire particle. More extensive (e.g. Cu2+-catalyzed) oxidation
of lipoproteins also affects the apoproteins either by direct free radical
attack or modiﬁcation by oxidized lipids leading to dramatic changes
in particle recognition by receptors. Copper-oxidized LDL uptake into
cells is mediated by the scavenger receptor which is a hallmark in ath-
erogenesis. It leads to unregulated cholesterol import into macro-
phages and eventually to the formation of foam cells [25]. The
detrimental modiﬁcation of apoB is due to the reaction with a series
of aldehydes including MDA, HNE and core aldehydes generated
from steryl esters and triacylglycerols, and last but not least oxidized
phospholipids including POVPC, Poxno-PC and the keto lipid KDdia-
PC (see Section 1). All these compounds mask the lysine clusters
which represent the receptor docking sites in LDL. As a consequence,
they render the particle more negative which makes it a good ligand
for scavenger receptors [34]. Furthermore, lipid oxidation products in-
teract with Toll-like receptors [35–39]. Recent studies provided evi-
dence that interactions of oxidized phospholipids and oxidized LDL
with TLR2 and CD36 trigger apoptosis in macrophages which suffered
from ER stress induced by Thapsigargin [40].
Notably, interaction of oxLDL with cells is competitively inhibited
by the POVPC-albumin complex [41,42] showing that the lipid-
modiﬁed protein domains are involved in these processes. The albu-
min–lipid conjugate effectively competes with oxLDL uptake by mac-
rophages [43,44]. The same modiﬁed protein also inhibits the uptake
of oxLDL by cells transfected with the scavenger receptor CD36 [45].
The same effect was observed if particles prepared from a total
oxLDL lipid extract were used instead of the lipoprotein.
Schiff base formation in LDL was visualized using ﬂuorescent alde-
hydophospholipids [20]. After exposure of LDL to BY-POVPE (a head-
group-labeled POVPC analog), a distinct ﬂuorescent band correspond-
ing to the imine (!) can be seen after electrophoresis on an agarose
gel. The labeled particle migrates faster than native LDL since it has
lost several positive charges. If the imine adduct is chemically re-
duced, the stable ﬂuorescent amine adduct of apoB can be detected
also after SDS electrophoresis. The ﬂuorescent LDL imine adduct
loses its labeled aldehydophospholipid if exposed to other amino nu-
cleophiles [20]. This good exchangeability of aldehydophospholipids
is physiologically relevant. Aldehydophospholipids are likely to con-
tribute to the activatory effect of oxLDL on the prothrombinase com-
plex [46,47]. Reductive stabilization of Schiff bases in this particleabolished this activity because the amine bound lipid components
are no longer exchangeable. The stimulatory properties of oxLDL are
mimicked by an ethanolamine phospholipid extract isolated from
the oxidized lipoprotein. Obviously, this phospholipid fraction and
proteins are nucleophiles capable of covalently binding (phospho)
lipid aldehydes and removing them from other nucleophilic partners.
Again, the lipid–lipid adducts are only active on the prothrombinase
complex if added in the original imine form. After chemical reduction,
they lose this activity.
Imine-bound POVPC is recognized in oxLDL as well as in POVPC-
albumin conjugates by the antibody E06 [41,43]. This speciﬁc interac-
tion is still maintained if the imines are reduced with NaCNBH3 [41].
From this data it can be inferred that the speciﬁc antigen-antibody
binding is solely due to the choline phospholipid head group and
does not depend on the type of lipid protein bonding. E06 as a protein
can also undergo direct binding to POVPC by Schiff base formation,
just as any other protein does.
HDL is also highly susceptible to oxidation [48]. Oxidative HDL
modiﬁcation is associated with changes in biophysical and immuno-
logical (see above) properties of apoAI and apoAII due to proteinmod-
iﬁcation by malondialdehyde, hydroxynonenal [49], neutral core
aldehydes and aldehydophospholipids. The existence of phospholip-
id–protein adducts in oxHDL was initially inferred from the increase
in phosphorus content of isolated HDL apoproteins [50]. This effect
correlated with the extent of lipoprotein oxidation and the formation
of Poxno-PC and POVPC (see Section 1). Modiﬁcation of HDL apopro-
teins by phospholipid aldehydes also elicits physiologically unfavor-
able effects [50]. Under physiological conditions, HDL removes
cholesterol from the arterial wall to deliver it by receptor-mediated
uptake into the liver. These beneﬁcial properties are lost, if the particle
is modiﬁed e.g. by Schiff base formation with lipid aldehydes. Modi-
ﬁed ApoAI as a component of oxHDL or if isolated after incubation
with Poxno-PC or POVPC was efﬁciently taken up by THP-1 macro-
phages [50]. The most likely receptor candidates for this process are
CD36 and SR-BI [51]. OxHDL is a potent inhibitor of oxLDL binding to
SR-BI. These results support the assumption that HDL modiﬁed by
lipid aldehydes is largely recognized by the same receptors as modi-
ﬁed LDL. They lead to an uncontrolled uptake of (oxidized) lipids by
vascular cells thus contributing to foam cell formation and initiating
the development of atherosclerosis [50]. Removal of cholesterol from
the vascular wall (reverse cholesterol transport) is an important anti-
atherogenic function of HDL. This beneﬁcial process is impaired by
modiﬁcation of apoAI by malondialdehyde [52] and it is likely that
phospholipid aldehydes show similar effects.
Oxidation of lipoprotein (a) (Lp(a)) represents a particular aspect
of vascular pathophysiology. This lipoprotein is basically an LDL par-
ticle which is associated with the apolipoprotein (a) the size of
which varies depending on the Lp(a) isoform. Lp(a) has been identi-
ﬁed as the main carrier of oxidized phospholipids in blood plasma
[53,54]. These ﬁndings are interesting insofar as Lp(a) is a risk factor
for atherosclerosis independent of LDL. To date it is not known how
the individual lipid aldehydes inﬂuence the biological properties of
this particle. Schiff base formation between phospholipids and apoB
of the “LDL core” on the one hand and apo(a) on the particle surface
on the other hand can be expected to induce very different effects
on lipoprotein structure and activity.
3.3. Modiﬁcations of proteins in cells
Oxidized phospholipids can be delivered to cells by different
donor systems including lipid–protein complexes and lipoproteins.
Since oxidized phospholipids are very polar, it can be expected that
a certain fraction is transferred to cells through the aqueous phase.
Lipid uptake has been studied by ﬂuorescence microscopy using suit-
ably labeled ﬂuorescent lipid analogs [20]. Single molecule studies
showed that labeled oxidized phospholipids rapidly incorporate into
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bound PGPC and POVPC analogs (see above) are also easily available
for cells. Oxidized phospholipids are abundant in oxidized lipopro-
teins [25]. Lipid uptake from these particles into cells is also very
fast. Internalization of the entire lipoprotein via receptors facilitates
but is not exclusively required for the latter process, since the highly
amphipathic lipid oxidation products spontaneously exchange be-
tween proteins, lipoprotein and cell surfaces [20]. It has already
been highlighted that even the covalently bound aldehydophospholi-
pids POVPC and Poxno-PC are freely available for this exchange since
Schiff bases are subject to modiﬁcation by competing nucleophiles
such as aminophospholipids and proteins.
Several attempts have already been made to identify the primary
molecular targets of oxidized phospholipids in cells. In a proteome-
wide study, cellular protein targets of hydroxynonenal have been de-
termined [55]. To date, two proteomic approaches have been used to
identify the cellular proteins that are covalently modiﬁed by labeled
aldehydophospholipids. In these studies, cultured cells were incubat-
ed with the phospholipid aldehydes followed by reductive stabiliza-
tion of the formed imines with NaCNBH3. After separation, the
lipid-tagged proteins were detected, isolated, tryptically digested
and identiﬁed by mass spectrometry.
Gugiu et al. [56] identiﬁed protein targets of oxidized phospholip-
id mixtures carrying biotin as afﬁnity tag at the polar head group.
These experiments were performed using human aortic endothelial
cells (HAEC). The tagged proteins were isolated after binding to strep-
tavidin beads and separated by SDS gel electrophoresis. A large num-
ber of different membrane-bound and water soluble proteins were
identiﬁed, including structural and ﬁlament proteins, as well as pro-
teins involved in stress response. It will be the goal of future studies
to ﬁnd out what are the functions of these targets in aldehydopho-
spholipid toxicity (see below). The biological relevance of these data
depends of course on the extent to which the labeled lipid analogs re-
ﬂect the properties and interactions of their natural counterparts.
Gugiu et al. [56] provide good evidence that lipid labeling does not
signiﬁcantly alter the biological activities of the natural compounds.
From previous work, it is known that the biological activity of oxi-
dized phospholipids depends much more on the oxidized sn-2 acyl
chain than the polar head group. Oxidized phosphatidylethanolamine
(PAPE) and -choline (PAPC) induce IL-8 production in HAEC. Both,
oxPAPC and its labeled analog N-biotinyl-PAPE stimulated protein
synthesis and mRNA expression of the same inﬂammatory response
genes in various cells [56–58]. In addition, both compounds induced
a similar inﬂammatory response in HAEC. Finally, it could be shown
that unlabeled oxPAPC competed with the N-biotin-labeled lipid for
the same protein targets [56].
Stemmer et al. [20] used a ﬂuorescent POVPC analog carrying
BODIPY as a reporter ﬂuorophore boundto the nitrogen atom of the
head group. The authors identiﬁed the protein targets of the oxidized
phospholipids in cultured RAW 264.7 macrophages. The ﬂuorescence
label allowed direct sensitive detection of labeled proteins by a laser
scanner on electrophoresis gels. After labeling of the live cells, tagged
proteins were identiﬁed in total cell lysates after 2-D gel electrophore-
sis or in a total membrane fraction after separation by 1-D SDS gel
electrophoresis. In both cases a large number of protein families
with different functions were detected, including proteins involved
in stress response, apoptosis, lipid metabolism and transport. Notably,
the protein patterns on the electrophoresis gels clearly showed that
protein tagging by the lipid was selective and by no means random.
This phenomenon may be due to the fact that Schiff base formation
in biological systems depends on several parameters including the
pK of the reacting amino groups, the intracellular localization and ac-
cessibility of the affected proteins [20,59]. The selectivity of protein
modiﬁcation by the phospholipid aldehyde does not depend on the
concentration of the oxidized phospholipid. Exposure of the cells to
different lipid amounts always generated the same ﬂuorescent proteinpattern. We have evidence that ﬂuorescent oxidized phospholipids
may also be considered reliable analogs of their natural parent mole-
cules. The ﬂuorescent and the unlabeled lipids elicit the same apopto-
tic signaling in cells. In addition, the reaction of the target proteins
with ﬂuorescent and unlabeled lipid is competitive. Fluorescence tag-
ging of cellular proteins by the latter compounds is abolished by
POVPC in a concentration-dependent manner.
Ongoing studies in our laboratory aim at elucidating the iden-
tiﬁed POVPC targets as functional components of oxidized phos-
pholipid toxicity. On the one hand, FRET experiments will be
performed to determine the spatial proximity of GFP/RFP-tagged tar-
gets and the ﬂuorescent POVPC. In addition, genes of the respective
proteins will be knocked down and the inﬂuence on lipid toxicity in
the cells will be measured. The functional approach is expected to im-
prove our understanding of oxidized phospholipid toxicity in lipid-
associated diseases and to help identify pharmacological targets for
clinical intervention.
3.4. Consequences of protein modiﬁcation by phospholipid aldehydes
Modiﬁcation by aldehydophospholipids may profoundly change
the molecular properties of polypeptides, including net charge, con-
formation, state of association, enzymatic and signaling functions
and last but not least, biological recognition, e.g. by receptors and
the immune system (see Sections 2 and 3) (Fig. 3). These modiﬁca-
tions on the molecular level lead to dramatic physiological conse-
quences contributing to the onset or progression of diseases. Causal
relationships between protein modiﬁcation, e.g. in lipoproteins, and
lipid-associated diseases have been the focus of numerous studies
for many years. Using chemically deﬁned oxidized phospholipids, it
is possible to identify the contribution of different lipid components
to the biological activities of oxidized lipoproteins. Both POVPC and
and its sn-2 carboxy analog PGPC mediate harmful effects of oxidized
LDL on the cells of the arterial wall [5,56]. However, the targets and
pathways affected by these phospholipids are different. High amounts
of POVPC are found in oxLDL and atherosclerotic plaques of mice and
humans [8]. It activates the expression of speciﬁc adhesion molecules
responsible for monocyte binding [8]. This effect seems to depend on
Schiff base formation of POVPC with its primary targets because it is
abolished if the phospholipid aldehyde is chemically reduced before
addition to the cells [60]. Sustained exposure of vascular cells to
POVPC or PGPC leads to apoptosis of vascular cells [5]. Again, the
mechanisms of toxicity are different. The aldehydophospholipid acti-
vates an acid sphingomyelinase in cultured vascular smooth muscle
cells [5] and macrophages (Stemmer et al. unpublished) within mi-
nutes. As a consequence, ceramide is formed which mediates the apo-
ptotic signal. PGPC leads to a slow but sustained ceramide formation
over hours. The enzymes contributing to this phenomenon are still
subject to identiﬁcation. According to recent work, ER stress and its bi-
ological consequences in macrophages are a major component of oxi-
dized phospholipid toxicity [40].
Proteins conjugated to aldehyde (choline) phospholipids on lipo-
proteins and cell surfaces induce the formation of autoantibodies
which can be detected in blood plasma [44]. The same immune re-
sponse is likely to be triggered by so-called microparticles which are
released from apoptotic cells and contain high amounts of oxidized
phospholipids [43,61–63] (see Section 3.5 and the chapter by C. Bind-
er in this special issue). Wang et al. [64] performed a well designed
experiment twenty years ago to prove the formation of speciﬁc auto-
antibodies against a chemically deﬁned aldehydophospholipid. They
prepared Schiff bases from bovine thyroglobulin and a PAF analog
containing an ω-aldehydoalkyl chain in position sn-1. After chemical
stabilization by reduction, this complex was used for antibody pro-
duction. The antibody was speciﬁc for the protein-associated PAF an-
alog and showed only minor activity towards lyso-PAF, plasmalogens
and other phospholipids.
Fig. 3. Schematic representation of aldehydo-phospholipid exchange and its biological consequences. Phospholipid aldehydes form covalent Schiff bases with free amino groups of
proteins and aminophospholipids. The phospholipid electrophiles are exchangeable between proteins, lipoproteins and cell surfaces, since the imines are subject to reaction with
competing nucleophiles. (Lipo-)Proteins modiﬁed by aldehydo-phospholipids interact with receptors on the cell surface thereby triggering intracellular signaling cascades in a
concentration- and time-dependent manner. Cooperative interactions of lipid-modiﬁed proteins with different receptors, e.g. CD 36 and TLRs, may lead to speciﬁc consequences (ap-
optosis or cell proliferation) depending on the cell surface components involved [38,40]. In addition, the toxic lipids may alter the organization of themembrane lipid bilayer and as a
consequence unspeciﬁcally modify the activities of signaling and enzyme proteins. Finally, aldehydo-phospholipids can enter the intracellular space and modify protein localization
and activities after Schiff base formation and lipidation. The biological consequences of the latter processes are currently subject to investigation [20]. In summary, the toxicity of
oxidized phospholipids is due to a multifactorial phenomenon which is based both on the lipophilic character of these compounds and their selective interactions of proteins. If
the target cells are components of the vascular wall, all these molecular events will contribute to the initiation and progression of atherosclerosis depending on the individual phys-
iological circumstances. Modiﬁcation of soluble proteins, lipoproteins and cellular proteins by aldehydophospholipids generates autoantigens which elicit an autoimmune response.
The biological implications of this phenomenon are discussed in this special issue (see the chapter by C. Binder). Finally, oxidized phospholipids give rise to the formation of mem-
brane vesicles. The resulting microparticles are spread through the circulation to various organs and can elicit toxic effects far distant from their site of origin.
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topes have been generated for analytical and diagnostic purposes. The
anti-oxLDL antibody FOH1a/DLH3 recognizes modiﬁed apoB in oxi-
dized LDL [65]. This antibody does not react with MDA-treated, acety-
lated or native LDL. However, it speciﬁcally binds to a series of
polypeptides associated with POVPC or Poxno-PC [65]. Hörkkö et al.
[44] produced monoclonal IgM antibodies from apoE-deﬁcient mice
(EO-autoantibodies), which bind to oxLDL. A widely used antibody
is EO6 which speciﬁcally recognizes the polar head groups of oxidized
but not native choline phospholipids [44]. Consistently, it inhibits the
binding of copper-oxidized LDL as well as POVPC-serum albumin ad-
ducts to mouse macrophages [44]. Epitopes for EO-autoantibodies
have also been found in human arteriosclerotic lesions and in circulat-
ing human LDL [42] providing evidence that aldehydophospholipid-
associated proteins also exist in vivo. It has to be emphasized that
covalent modiﬁcation of apoB by oxidized phospholipids is not a re-
quirement for oxLDL recognition by CD36 [66]. On the one hand, ApoB
may not only be modiﬁed by lipid electrophiles but also by direct free
radical attack by reactive oxygen, nitrogen or chlorine species. The
result would be the same, namely a loss of lysines and an increase
in net negative charge. On the other hand, negatively charged oxi-
dized phospholipids such as PGPC or Paze-PC ae also inducers of
CD36 binding. They do not covalently modify (apolipo)proteins butadd electrostatic charges to the phospholipid monolayer of the lipo-
protein particle.
EO6 has also been found to bind equimolar amounts of POVPC in
protein-free form and this is plausible, too [41]. The free lipid alde-
hyde may also give rise to Schiff base formation with the antibody
without any need of speciﬁc immune recognition of the lipid in
protein-bound form. In the case of protein-conjugated aldehydopho-
spholipids, EO6 recognizes the choline phospholipid head group irre-
spective of peptide sequence.
Proteins are subject to modiﬁcation by (phospho)lipid aldehydes
not only on (lipo)protein and cell surfaces. There is evidence that in-
tracellular proteins also form lipid–protein Schiff bases [56]. Such
lipid–protein adducts have been identiﬁed by proteomic analysis
after afﬁnity tagging with labeled lipid analogs (see Section 3.3). In
addition, protein-bound choline phospholipid aldehydes have been
detected using the speciﬁc antibody E06 [44].
It has been shown that modiﬁcation of intracellular proteins by
hydroxynonenal and malondialdehyde leads to alterations of inter-
molecular interactions and biochemical functions [9,10,23,29,67–70].
The physiological consequences of protein conjugation to phospholip-
id aldehydes inside cells will be subject to future investigations. A ﬁrst
step in this direction is the identiﬁcation of the primary target candi-
dates (see Section 3.3).
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and formation of microparticles
Uptake of oxidized phospholipids into cells as components of lipo-
proteins or other carrier systems (see Section 3.2) elicit cytotoxic ef-
fects [5,40]. Oxidative (lipid) stress may in turn stimulate the
intracellular formation of such compounds and potentiate their toxic-
ity in cells. The toxic effects of oxidized phospholipids are not only re-
stricted to the site of their formation. Especially the truncated and
highly modiﬁed derivatives are so polar that they readily exchange
between cells through the aqueous phase and therefore can partition
within a certain area of the affected tissue. A much more efﬁcient way
is the systemic administration of phospholipid oxidation products by
vesicle (microparticle) transport through the circulation [61–63].
Sustained exposure to oxidized phospholipids can induce apoptosis
or even necrosis [5]. Both types of cell death are accompanied by
the release of membrane fragments either in a very controlled pro-
cess leaving the parent cell intact (apoptotic blebs) or in a less deﬁned
way leading to cell lysis and formation of cell debris (necrosis). Mem-
brane vesicles secreted from apoptotic cells contain high amounts of
oxidized phospholipids [61–63] and as a consequence possess the ca-
pacity of transmitting the toxic compounds within tissues and the en-
tire organism. Yang et al. [71] recently showed that levels of
peroxidized phospholipids and their truncation products including
HpODE-PC, Paze-PC and PGPC are elevated in blood plasma of rats
and humans with steatohepatitis induced by chronic exposure to eth-
anol. The respective compounds contain sn-2 carboxyacyl chains. The
analogous sn-2 aldehydoacyl phospholipids were not mentioned in
this study though it seems likely that the latter compounds are also
formed under oxidative stress in the liver. Data from independent
studies using the antibody EO6 are in line with this assumption.
They have provided evidence that protein-associated choline phos-
pholipid head groups are components of microparticles isolated
from blood plasma (C. Binder, personal communication).
The mechanism of (apoptotic) membrane blebbing may be based
on different lipid and protein effects. First of all, the oxidized phos-
pholipids themselves can increase the tendency of a biological mem-
brane to release vesicles and these effects depend on minor
differences in phospholipid structures to a large extent. In a time-
resolved ﬂuorescence microscopy study, Rhode et al. [19] showed
that ﬂuorescent PGPC induces the formation of endosomes within
seconds [19]. In addition, this phospholipid gives rise to massive for-
mation of exocytic plasma membrane vesicles (apoptotic blebs)
(Stemmer et al. unpublished). Both effects can be explained in
terms of phospholipid geometry. PGPC is conically shaped since it
contains a large head group and only a narrow hydrophobic tail
(sn-1 acyl chain) [18].
The aldehydophospholipid POVPC behaves entirely different as
compared to its sn-2 carboxyacyl counterpart. It is internalized by cul-
tured cells very slowly and the amount of exocytic particles released
by this lipid is much smaller. In addition, the protein pattern of the re-
spective microparticles is entirely different. Obviously, membrane
blebbing induced by either phospholipid is a very speciﬁc process
which does not only affect the amount but also the protein composi-
tion of microparticles (Stemmer et al. unpublished). It remains to be
clariﬁed to what extent the lipidomes of such membrane fragments
are inﬂuenced. As discussed already in the previous chapters, mem-
brane properties of the carboxylate lipids are entirely biophysical
and entirely bound to the phospholipid bilayer. In contrast, POVPC
can form Schiff bases with proteins and aminophospholipids (phos-
phatidylcholine and phosphatidylserine). Especially the lipid–lipid
adducts are likely to be compounds that can destabilize bilayer struc-
tures. Khandelia and collaborators performed molecular dynamics
studies and found that accumulation of such lipid condensation prod-
ucts leads to breakdown of phosphatidylcholine bilayers (H. Khande-
lia, personal communication.)Apart from direct effects on microparticle formation, secondary ef-
fects of oxidized phospholipids may also come into play. POVPC rap-
idly activates a transient increase of acid sphingomyelinase activity
within minutes (see above) which generates ceramide and thereby
mediates cytotoxic signaling. It remains to be clariﬁed whether this
effect is due to direct lipidation of the enzyme by the phospholipid al-
dehyde. In contrast to POVPC, PGPC induces a slow but sustained in-
crease in ceramide levels. The enzymes responsible for the latter
effect are still subject to identiﬁcation. In an elegant experiment, Kin-
nunen and colleagues demonstrated that ceramide shows a high ca-
pacity of inducing vesicle release from membranes [72]. If ceramide
was generated from sphingomyelin by sphingomyelinase in large
unilamellar vesicles, exo- or endocytosis was observed depending
on the localization of the sphingolipid hydrolase (outside and inside,
respectively). The time scale for ceramide formation under the inﬂu-
ence of PGPC and POVPC is very different. As a consequence both
lipids might contribute to the apparent microparticle proﬁles, e.g. in
plasma, to a different extent with respect to time dependence,
amount and composition of lipid particles.
Finally, cell death is associated with the externalization of phos-
phatidylserine. The respective phospholipid fraction contains oxi-
dized fatty acyl chains. In addition, it can form lipid–lipid adducts
with aldehydophospholipid and generate new toxic compounds. It
will be a challenge of future studies to ﬁnd out whether and to
what extent Schiff base formation by aldehydophospholipids with
this and other membrane components plays a role in the formation
and the toxic effects of microparticles.
4. Perspectives
Aldehydophospholipids are covalently bound components of pro-
teins in solution, in lipoproteins and in cells. Their biological activities
have mainly been studied with emphasis on their role as components
of oxidized lipoproteins and their contribution to atherogenic pro-
cesses. Evidence has also been provided that these compounds and
other oxidized phospholipids, are associated with various other dis-
eases although it is not clear whether they are causally involved in
the development or are generated as a consequence of the patholog-
ical conditions. A particular facet of the pathophysiology of aldehydo-
phospholipids is their role in microparticle formation that is lipid-
speciﬁc and contributes to their systemic cytotoxicity. The role of
this lipid class in the formation and activity of microparticles is un-
known. A priori, their biological activities need not always to be det-
rimental. It remains to be elucidated whether and under what
circumstances aldehydophospholipids and their Schiff base adducts
exert beneﬁcial effects in the organism.
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